GSK insiders: Share Reward Plan purchases of 18 shares at £14.08 on 11 Aug

Rhea-AI Filing Summary

GSK plc reported that multiple senior managers, including CEO Emma Walmsley and CFO Julie Brown, acquired Ordinary Shares under the company’s Share Reward Plan. Each named participant purchased 18 Ordinary Shares (comprised of 9 partnership shares and 9 matching shares) at a price of £14.0845 per share on 11 August 2025. All transactions were executed on the London Stock Exchange (XLON). The report lists several other executives and senior officers making identical purchases under the same plan; the disclosures are routine notifications of employee share-plan acquisitions.

Insights

Financial Analyst

TL;DR: Routine, small-scale insider acquisitions under the company share plan; immaterial to valuation but signals plan participation.

The filing details uniform acquisitions by multiple PDMRs of 18 Ordinary Shares each at £14.0845 on 11 August 2025 via the London Stock Exchange. These purchases were made under GSK's Share Reward Plan and reflect standard employee/share-plan activity rather than open-market strategic accumulation. Given the small volumes disclosed per individual, the transactions are immaterial to enterprise value and unlikely to move market perceptions materially.

Corporate Governance Expert

TL;DR: Clear, timely regulatory disclosures of share-plan acquisitions by senior officers; governance process appears followed.

The Form 6-K provides transparent, specific notifications for each named PDMR, including role, instrument, volumes (9 partnership and 9 matching shares), price per share, and execution venue. The uniform structure and identical terms across listed executives indicate these are plan-driven allocations. From a governance perspective, the filings satisfy insider transaction disclosure requirements and document senior management participation in the company’s reward framework.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0845	9 (partnership shares)
			£14.0845	9 (matching shares)
			d)	Aggregated information
Aggregated volume Price	18 Ordinary Shares £14.0845
e)	Date of the transaction	2025-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0845	9 (partnership shares)
			£14.0845	9 (matching shares)
		d)	Aggregated information
Aggregated volume Price	18 Ordinary Shares £14.0845
e)	Date of the transaction	2025-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0845	9 (partnership shares)
			£14.0845	9 (matching shares)
			d)	Aggregated information
Aggregated volume Price	18 Ordinary Shares £14.0845
e)	Date of the transaction	2025-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0845	9 (partnership shares)
			£14.0845	9 (matching shares)
		d)	Aggregated information
Aggregated volume Price	18 Ordinary Shares £14.0845
e)	Date of the transaction	2025-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0845	9 (partnership shares)
			£14.0845	9 (matching shares)
			d)	Aggregated information
Aggregated volume Price	18 Ordinary Shares £14.0845
e)	Date of the transaction	2025-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0845	9 (partnership shares)
			£14.0845	9 (matching shares)
		d)	Aggregated information
Aggregated volume Price	18 Ordinary Shares £14.0845
e)	Date of the transaction	2025-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0845	9 (partnership shares)
			£14.0845	9 (matching shares)
			d)	Aggregated information
Aggregated volume Price	18 Ordinary Shares £14.0845
e)	Date of the transaction	2025-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0845	9 (partnership shares)
			£14.0845	9 (matching shares)
		d)	Aggregated information
Aggregated volume Price	18 Ordinary Shares £14.0845
e)	Date of the transaction	2025-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.0845	9 (partnership shares)
			£14.0845	9 (matching shares)
		d)	Aggregated information
Aggregated volume Price	18 Ordinary Shares £14.0845
e)	Date of the transaction	2025-08-11
f)	Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: August 12, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider transactions did GSK (GSK) report on Aug 11, 2025?

Multiple senior executives acquired 18 Ordinary Shares each (9 partnership + 9 matching) at £14.0845 per share on 11 August 2025.

Which executives are named in the GSK Form 6-K insider notifications?

Named participants include Emma Walmsley (CEO), Julie Brown (CFO), James Ford, Sally Jackson, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse, and Victoria Whyte.

Under what programme were the GSK insider shares acquired?

All purchases were made under the company's Share Reward Plan and reported as acquisitions of Ordinary Shares.

On which exchange were the GSK insider transactions executed?

The transactions were executed on the London Stock Exchange (XLON).

What is the instrument and ISIN referenced in the filing?

The instrument is Ordinary shares of 31¾ pence each, ISIN GB00BN7SWP63.